RICHMOND, Va., May 6, 2014 /PRNewswire/ -- Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnostic biomarkers and therapeutic targets, today announced the appointment of Harry “Chip” Davis, Jr., Ph.D., as chief drug development officer. Dr. Davis will be leading the drug discovery group together with Szilard Voros, M.D., co-founder and CEO of G3.
“We are pleased that such an accomplished scientist will join G3 as chief drug development officer, and we welcome Chip to our team,” said Dr. Voros. “Chip’s deep knowledge of the biology of atherosclerosis, as well his experience in genomics and bioinformatics that have led to the development of a blockbuster drug, makes him a high-value addition to our team. We are looking forward to working with Chip on one of the most comprehensive datasets to identify disease-related pathways, new drug targets and biomarkers in cardiovascular disease.”
Dr. Davis has more than 25 years of experience in drug discovery and development. He is currently chief scientific officer for CVPath Institute, a not-for-profit organization in Gaithersburg, Md. Most recently, he held a position as a distinguished research fellow in the Cardiovascular/Atherosclerosis research group at the Merck Research Labs. Prior to the merger of Merck and Schering-Plough, he was at the Schering-Plough Research Institute, where he researched atherosclerosis and dyslipidemia as well as mechanisms of cholesterol absorption and metabolism including the intestinal sterol transporter NPC1L1. Dr. Davis and his colleagues discovered and developed ezetimibe (ZETIA®), for which he won the 2006 Discoverer’s Award, the highest scientific honor in the pharmaceutical industry. Additionally, he has patented a number of compounds and their uses, including several agents to treat hypercholesterolemia.
“I am delighted to join G3 and to participate in one of the most visionary and ambitious projects that has ever been undertaken in cardiovascular diseases,” said Dr. Davis. “G3’s GLOBAL study, which is nearing enrollment completion of 7,500 patients, is setting a new standard for biomarker and pharmaceutical target discovery. This is the first study to combine next-generation phenotyping, pan-omics and system-biology-based bioinformatics and will provide invaluable insights into the etiology of atherosclerosis.”
Dr. Davis received his Ph.D. from the University of Chicago after completing his graduate studies in the Department of Pathology, Specialized Center of Research in Atherosclerosis. In addition, he is a fellow of the American Heart Association Council on Arteriosclerosis.
About Global Genomics Group (G3)
G3 is a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnostic biomarkers and therapeutic targets. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.
For additional information, please visit www.globalgenomicsgroup.com
G3 Contacts
Media
Martina Schwarzkopf, Ph.D.
(212) 845-4292
martina.schwarzkopf@russopartnersllc.com
Corporate
Idean Marvasty
(404) 368-1554
idean.marvasty@globalgenomicsgroup.com
SOURCE Global Genomics Group (G3)
Help employers find you! Check out all the jobs and post your resume.
